Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
As of today (2026-07-29), the Trailing Annual Dividend Yield of Enzymatica AB is 0.00%.
The historical rank and industry rank for Enzymatica AB's Dividend Yield % or its related term are showing as below:
OSTO:ENZY's Dividend Yield % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 1.93 * Ranked among companies with meaningful Dividend Yield % only.
The growth rate is calculated with least square regression.
For more information regarding to dividend, please check our Dividend Page.
* Please note that "special dividend" is not included in the calculation of dividend per share and related fields.
Enzymatica AB (OSTO:ENZY) Dividend Yield % Explanation
Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.
Dividends may also qualify a lower tax rate for investors.
In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.
The historical data trend for Enzymatica AB's Dividend Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Enzymatica AB's Dividend Yield %, along with its competitors' market caps and Dividend Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Enzymatica AB Dividend Yield % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Enzymatica AB's Dividend Yield % distribution charts can be found below:
* The bar in red indicates where Enzymatica AB's Dividend Yield % falls into.
Enzymatica AB (OSTO:ENZY) has a Dividend Yield % of 0.00% as of Jul. 29, 2026. Dividend yield is the ratio of company dividends to the share price. View historical data on Enzymatica AB and its competitors. According to the industry distribution chart, Enzymatica AB ranks #999999 out of 513 companies in the Drug Manufacturers industry.
Is Enzymatica AB's Dividend Yield % too high?
Enzymatica AB's current Dividend Yield % is 0.00%. Based on the distribution chart, Enzymatica AB ranks #999999 out of 513 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Enzymatica AB has a GF Score™ of 58/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Enzymatica AB's Dividend Yield % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Enzymatica AB ranks #999999 out of 513 companies for Dividend Yield %. This places Enzymatica AB in the lower half of its industry. The industry median Dividend Yield % is 1.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Dividend Yield % for a Drug Manufacturers company?
The median Dividend Yield % among Drug Manufacturers companies is 1.93, based on 513 companies in the industry. Companies in the top quartile (top 25%) have a Dividend Yield % significantly above this median, while those in the bottom quartile fall well below. However, Dividend Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Dividend Yield % mean?
A high Dividend Yield % can signal that a stock is expensive relative to its fundamentals. Dividend yield is the ratio of company dividends to the share price. View historical data on Enzymatica AB and its competitors. For the Drug Manufacturers industry, the median Dividend Yield % is 1.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Enzymatica AB's current Dividend Yield % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Enzymatica AB stock overvalued right now?
Based on GuruFocus' analysis, Enzymatica AB (OSTO:ENZY) is currently considered Modestly Undervalued. The stock's GF Value™ is kr2.13, compared to a current price of kr1.85 — trading 13.4% below its estimated fair value. The current Dividend Yield % is 0.00%. Enzymatica AB's overall GF Score™ is 58/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Dividend Yield % calculated?
Dividend Yield % is calculated from a company's financial statements. For Enzymatica AB (OSTO:ENZY), the current Dividend Yield % is 0.00% as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Enzymatica AB (OSTO:ENZY) Overvalued in 2026?
Based on GuruFocus' analysis, Enzymatica AB stock appears to be undervalued.
The current stock price of kr1.85 is trading 13.4% below its estimated GF Value™ of kr2.13.
GuruFocus considers Enzymatica AB to be Modestly Undervalued.
Key valuation signals for OSTO:ENZY:
Dividend Yield %: 0.00%
GF Value™: kr2.13 vs. price of kr1.85 (13.4% below fair value)
No single metric tells the full story. See the OSTO:ENZY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Enzymatica AB is a life science company that develops and sells medical devices against infectious diseases, based on a barrier technology, which includes marine enzymes. Its product ColdZyme Mouth Spray prevents cold and reduces disease period.
58GF Score
Get the complete analysis for OSTO:ENZY
Dividend Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:ENZY has been successfully added to your 
